Member Info for MIdnightPete

Yes. Some meat on the bones regarding uplisting and bank licences will be very welcome. With inflation looking sticky, those bank licences dropping could provide a tremendous fillip to interest income.

Very far from sure a US listing is the answer to our prayers. Have folk spent any time trading Nasdaq biotechs?

Scores of companies boasting very credible programmes floundering about with sub $150m mcs.

Scrabbling about for cash. Pulverised for poor commercial decisions.

Sure, the US market can sustain very big moves - 500%+ - over relatively short periods, but what does that say about the initial (mis)pricing of the equity?

And, last summer, BG closed their British small companies fund..

"Its largest holdings included Burford Capital at 8.3%, Alpha FX at 6.6% and promotional products supplier 4imprint at 6.3%."

https://portfolio-adviser.com/baillie-gifford-closes-141m-british-smaller-companies-fund/

Fair to say, the Uk small-cap space is an infuriating place to be right now.

Nice to have a decent pile to reassure clients and regulators but beyond that, I favour further M&A activity. I suspect there are still bargains about.

Though, I concede, given the painstaking, diligent approach of management this is unlikely to happen so soon after the Cobase buy.

I guess a couple of things might be holding the SP back.

A belief rates are going to quickly head back down and the boost to cash generation will be shortlived.

More fundamentally: a fear that AI is going to erode the FX business. I don't know enough to comment on that.

But I do know that it's the Alt Banking division that I'm most excited about...

Would love to say otherwise, but GIVEMESUNSHINE is reading this correctly.

Underwhelming sales.

Great science and fabulous potential.

AMRX sp 14months ago: 50 cents

Today: $27

Worth mentioning that NY was not the first to pass that sort of legislation. Around a dozen beat them to it, including California. (Link courtesy of hg44):

https://www.fightcancer.org/releases/governor-newsom-signs-game-changing-legislation-aimed-improving-health-outcomes-quality

Https://twitter.com/MACDcurlingup/status/1738348533999349957

The momentum building all the while. The legislation discussed below has just been passed in New York.

https://www.cbsnews.com/newyork/news/gov-kathy-hochul-reviewing-biomarker-testing-bill-that-doctors-say-is-game-changer-in-treating-cancer/

And, maybe a touch more interesting, BMY's license and collaboration deal with SystImmune for their PH1 ADC asset....

$800m upfront; a potential total of $8.4b.

https://finance.yahoo.com/news/systimmune-bristol-myers-squibb-announce-211500882.html

Https://twitter.com/KazzBio/status/1727420996850794625/photo/1

The American usage of "through" can pose difficulties for the uninitiated, but be very clear: $562 million was the total lifetime revenue across two and a bit yrs.

Promotion of the drug was halted in Jan 2019. Q4 2018 sales were $83.5 million.

https://investor.lilly.com/static-files/ed651fe8-e9ba-434b-be7f-05196b2ba91b

Https://twitter.com/paras_biotech/status/1720819509571747888

The note is a nonsense.

The platform is worth many billions.

But best not to propagate Twitter fictions...Lartruvo sales:

https://www.spglobal.com/marketintelligence/en/news-insights/trending/U8kDopQ1gAqIEBKkvIb1ZA2

Merck collaboration:

Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology and clinical development capabilities to advance and expand the reach of ADCs for patients across multiple types of cancer

Daiichi Sankyo and Merck to co-develop and co-commercialize patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan worldwide except for Japan where Daiichi Sankyo retains exclusive rights

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months, and may make additional payments of up to $16.5 billion contingent upon the achievement of future sales milestones, for a total potential consideration of up to $22 billion

https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/

Https://www.roadtoautonomy.com/in-cabin-sensing-technology/

Very decent 40mins+ with Paul Mc.

Flagged by the ever-industrious Warren Messenger on Twitter.

There we go. That has the look of an RNS prompted by shareholder queries.

Of greater interest to me: the progress of the licence applications.

Q3 interest income is around the corner. 4% on a £2.3b balance would be just super, thank you so much.

It's our stuff, Chris.

Saw this only because I'm gonna take a punt on Indie today...seems to be in a buyable spot.